Shares of Concert Pharmaceuticals Inc (NASDAQ:CNCE) have earned a consensus rating of “Hold” from the nine brokerages that are currently covering the company, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation, three have given a hold recommendation and four have given a buy recommendation to the company. The average twelve-month price objective among brokerages that have issued a report on the stock in the last year is $29.33.

CNCE has been the topic of several analyst reports. ValuEngine upgraded Concert Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Monday, July 30th. Mizuho reiterated a “buy” rating and issued a $27.00 target price on shares of Concert Pharmaceuticals in a research note on Thursday, August 2nd. HC Wainwright reiterated a “buy” rating on shares of Concert Pharmaceuticals in a research note on Friday, August 3rd. Janney Montgomery Scott initiated coverage on Concert Pharmaceuticals in a research note on Thursday, September 13th. They issued a “neutral” rating on the stock. Finally, BidaskClub downgraded Concert Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Wednesday, August 22nd.

In other Concert Pharmaceuticals news, COO Nancy Stuart sold 31,418 shares of Concert Pharmaceuticals stock in a transaction that occurred on Tuesday, July 10th. The stock was sold at an average price of $17.87, for a total value of $561,439.66. Following the transaction, the chief operating officer now directly owns 116,085 shares in the company, valued at approximately $2,074,438.95. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 9.40% of the company’s stock.

Several hedge funds have recently made changes to their positions in CNCE. Systematic Financial Management LP boosted its stake in shares of Concert Pharmaceuticals by 9.8% in the second quarter. Systematic Financial Management LP now owns 72,120 shares of the biotechnology company’s stock valued at $1,214,000 after buying an additional 6,440 shares in the last quarter. Acadian Asset Management LLC boosted its stake in shares of Concert Pharmaceuticals by 11.3% in the second quarter. Acadian Asset Management LLC now owns 941,282 shares of the biotechnology company’s stock valued at $15,841,000 after buying an additional 95,863 shares in the last quarter. Cambria Investment Management L.P. purchased a new stake in shares of Concert Pharmaceuticals in the second quarter valued at approximately $216,000. Ingalls & Snyder LLC boosted its stake in shares of Concert Pharmaceuticals by 1.2% in the second quarter. Ingalls & Snyder LLC now owns 1,337,862 shares of the biotechnology company’s stock valued at $22,516,000 after buying an additional 15,800 shares in the last quarter. Finally, Municipal Employees Retirement System of Michigan purchased a new stake in shares of Concert Pharmaceuticals in the first quarter valued at approximately $1,539,000. Institutional investors own 73.26% of the company’s stock.

CNCE traded up $0.02 during trading on Friday, hitting $13.77. 502 shares of the stock were exchanged, compared to its average volume of 95,829. The firm has a market cap of $321.96 million, a price-to-earnings ratio of 3.38 and a beta of 1.00. Concert Pharmaceuticals has a 1-year low of $12.33 and a 1-year high of $30.71.

Concert Pharmaceuticals (NASDAQ:CNCE) last released its quarterly earnings results on Thursday, August 2nd. The biotechnology company reported ($0.57) EPS for the quarter, topping the consensus estimate of ($0.62) by $0.05. Concert Pharmaceuticals had a negative return on equity of 19.73% and a net margin of 67.52%. sell-side analysts predict that Concert Pharmaceuticals will post -2.06 earnings per share for the current fiscal year.

Concert Pharmaceuticals Company Profile

Concert Pharmaceuticals, Inc operates as a clinical stage biopharmaceutical company. The company discovers and develops novel small molecule drugs for use in the treatment of various pulmonary diseases, including autoimmune and inflammatory diseases, and central nervous systems disorders. Its product candidates include AVP-786, a combination of deudextromethorphan and an ultra-low dose of quinidine, which is in Phase 3 clinical trials for the treatment of neurologic and psychiatric disorders, including agitation associated with Alzheimer's disease; CTP-730, a deuterated analog of apremilast that has completed the Phase 1 clinical trials for the treatment of inflammation or cancer; JZP-386, which has completed the Phase 1 clinical trials for the treatment of patients with narcolepsy; and CTP-543, which is in Phase 1 clinical trials for use in the treatment of alopecia areata.

Featured Story: Dow Jones Industrial Average (DJIA)

Analyst Recommendations for Concert Pharmaceuticals (NASDAQ:CNCE)

Receive News & Ratings for Concert Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Concert Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.